• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
mRNA

mRNA

We provide customized, high-quality and scalable mRNA production by in vitro transcription (IVT).

The services are integrated with high-quality plasmid production and discovery scale mRNA LNP formulation.

We offer a customized synthesis of mRNA for screening to preclinical studies. Our high-quality mRNA transcripts are ideal for functional studies, therapeutics, diagnostics and vaccine production. IVT is the method of choice to produce long and stable RNA molecules such as mRNA, guide RNA, SaRNA or long RNA when chemical synthesis is not possible.

Irrespective of scale, mRNA molecules go through rigorous in-process and final quality checks through a set of standard and customized analytical methods. Our mRNA processes are flexible and can be customized as per client needs.

Our mRNA services are integrated to high-quality plasmid DNA production, processing enzymes and other reagent generations. We provide high-throughput codon-optimized gene synthesis and cloning. We perform E. coli clone development, cell banking, E. coli fermentation and plasmid purification.

mRNA formulation: We support small scale mRNA formulation development and characterization.

Speak to our experts

In vitro transcription

  • Sequence design, gene synthesis and cloning
  • RNA transcripts from plasmids, PCR products and cDNA
  • Conventional and Self-amplifying RNA (SaRNA)
  • Flexibility to choose transcriptional promoter (T7 or SP6)
  • Normal unmodified mRNA synthesis
  • Use of modified bases in mRNA transcripts (Pseudo UTP etc.)
  • Several strategies for 5’ capping such as co-translational capping with Anti Reverse Cap Analog (ARCA)
  • Post-translational vaccinia capping
  • Options to choose from Cap0 and Cap1
  • Template-derived poly A tail or enzymatic incorporation in the IVT mRNA template
  • Optimization of mRNA translation and stability

Purification

  • Well-characterized in RNAse free environment
  • High-quality plasmid purification, characterization, and IVT template preparation
  • Method optimization for gram quantity
  • Plasmid DNA purification and characterization
  • Purification using lithium chloride precipitation and chromatography

Analytical control

  • Batch-to-batch consistency of the IVT mRNA
  • Bioanalyzer
  • Purity (tape station)
  • Length confirmation
  • Sequence confirmation by cDNA
  • Capping efficiency by mass-spec
  • Endotoxin measurement
  • SE-HPLC
  • DOT-BLOT
  • Immunogenicity testing for vaccine candidates

Why Aurigene Pharmaceutical Services?

Customized screening and scaling up strategies

In vitro transcription, purification and quality control

Customized formulation

Modernized state-of-the-art facility

Adaptable, scalable and high-quality

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack